BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 19959009)

  • 1. Molecular imaging (PET) of brain tumors.
    Basu S; Alavi A
    Neuroimaging Clin N Am; 2009 Nov; 19(4):625-46. PubMed ID: 19959009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in evaluation of primary brain tumors.
    Chen W; Silverman DH
    Semin Nucl Med; 2008 Jul; 38(4):240-50. PubMed ID: 18514080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
    Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
    J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New PET radiopharmaceuticals beyond FDG for brain tumor imaging.
    Gulyás B; Halldin C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):173-90. PubMed ID: 22617239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positron emission tomography imaging of brain tumors.
    Wong TZ; van der Westhuizen GJ; Coleman RE
    Neuroimaging Clin N Am; 2002 Nov; 12(4):615-26. PubMed ID: 12687915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography for radiation treatment planning.
    Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
    Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
    Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
    J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET of common enhancing malignant brain tumors.
    Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
    AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging gliomas with positron emission tomography and single-photon emission computed tomography.
    Bénard F; Romsa J; Hustinx R
    Semin Nucl Med; 2003 Apr; 33(2):148-62. PubMed ID: 12756647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET and brain tumor image fusion.
    Wong TZ; Turkington TG; Hawk TC; Coleman RE
    Cancer J; 2004; 10(4):234-42. PubMed ID: 15383204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging of hypoxic lesions in patients with gliomas by using positron emission tomography with 1-(2-[18F] fluoro-1-[hydroxymethyl]ethoxy)methyl-2-nitroimidazole, a new 18F-labeled 2-nitroimidazole analog.
    Shibahara I; Kumabe T; Kanamori M; Saito R; Sonoda Y; Watanabe M; Iwata R; Higano S; Takanami K; Takai Y; Tominaga T
    J Neurosurg; 2010 Aug; 113(2):358-68. PubMed ID: 19895196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.
    Pirotte B; Goldman S; Massager N; David P; Wikler D; Lipszyc M; Salmon I; Brotchi J; Levivier M
    J Neurosurg; 2004 Sep; 101(3):476-83. PubMed ID: 15352606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET with radiolabeled aminoacid.
    Crippa F; Alessi A; Serafini GL
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):151-62. PubMed ID: 22617237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
    Powles T; Murray I; Brock C; Oliver T; Avril N
    Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronuclear assessment of patients with epilepsy.
    Goffin K; Dedeurwaerdere S; Van Laere K; Van Paesschen W
    Semin Nucl Med; 2008 Jul; 38(4):227-39. PubMed ID: 18514079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positron emission tomography (PET) for diagnosis and monitoring of treatment for urological tumors].
    Machtens S; Boerner AR; Hofmann M; Knapp WH; Jonas U
    Urologe A; 2004 Nov; 43(11):1397-409. PubMed ID: 15502907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
    Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
    J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of PET imaging of neurological tumors with radiolabeled amino acids.
    Galldiks N; Langen KJ
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):70-82. PubMed ID: 25517079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
    Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
    Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.
    Pirotte B; Goldman S; Massager N; David P; Wikler D; Vandesteene A; Salmon I; Brotchi J; Levivier M
    J Nucl Med; 2004 Aug; 45(8):1293-8. PubMed ID: 15299051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.